NDLI: Assessment of the factors affecting the clinical outcomes of infection and safety of vaccines against SARS-CoV-2 among Egyptian patients

Content Provider	Springer Nature : BioMed Central
Author	Zidan, Amira A. Jad, Ahmed Yousef Zakaria, Nermine H. El-Hariri, Hazem M. El-Setouhy, Maged
Abstract	Background Understanding the factors that influence clinical outcomes of COVID-19 and the safety of various vaccines is important to inform public health strategies, particularly in diverse communities. This study aimed to assess the factors affecting the clinical outcomes of COVID-19 and vaccination safety among the Egyptian population. Methods In a retrospective study, we examined 1597 patients who tested positive for COVID-19. Among them, 1280 patients had received the vaccination, while 317 patients had not. We collected data from medical records, which included clinical characteristics, comorbidities, disease severity, type of vaccination, and adverse hematological effects postvaccination. We calculated the relative risk, odds ratio, and 95% confidence intervals (CIs). Results Among the 1,597 COVID-19 cases, 74.1% were mild, 24.8% were moderate, and 1.1% were severe. Significant factors for moderate/severe cases included male sex (RR 0.78, 95% CI 0.64–0.95), cardiovascular diseases (RR 1.86, 95% CI 1.32–2.64), respiratory diseases (RR 1.40, 95% CI 1.08–1.82), diabetes mellitus (RR 1.41, 95% CI 1.07–1.86), and previous COVID-19 infection (RR 1.22, 95% CI 1.02–1.46). Vaccination reduced the severity risk, with BBIBP-CorV (Sinopharm) showing a significant protective effect (OR 0.78, 95% CI 0.62–0.98). Clinical presentations varied, with 97.6% having an oxygen saturation ≥ 92%. Logistic regression indicated that male sex and BBIBP-CorV (Sinopharm) vaccination were protective factors. Linear regression revealed that the male sex increased hemoglobin and leucocyte counts, whereas BBIBP-CorV (Sinopharm) decreased leucocyte and platelet counts. Conclusion Vaccination, particularly with BBIBP-CorV (Sinopharm), significantly reduces COVID-19 severity among Egyptians, despite various clinical presentations and hematological effects. Clinical trial number Not applicable.
Related Links	https://bmcinfectdis.biomedcentral.com/counter/pdf/10.1186/s12879-024-10362-8.pdf
Ending Page	11
Page Count	11
Starting Page	1
File Format	HTM / HTML
ISSN	14712334
DOI	10.1186/s12879-024-10362-8
Journal	BMC Infectious Diseases
Issue Number	1
Volume Number	25
Language	English
Publisher	BioMed Central
Publisher Date	2025-03-19
Access Restriction	Open
Subject Keyword	Infectious Diseases Parasitology Medical Microbiology Tropical Medicine Internal Medicine BBIBP-CorV WIBP-CorV (sinopharm) ChAdOx1 nCoV-19 AstraZeneca Ad26.COV2.S Johnson & Johnson Moderna BNT162b2 mRNA (Pfizer-BioNTech) CoronaVac (Sinovac) Gam-COVID-Vac (Sputnik) COVID-19 vaccines Viral vector Messenger RNA (mRNA) Inactivated virus vaccines Efficacy Safety
Content Type	Text
Resource Type	Article
Subject	Infectious Diseases
Journal Impact Factor	3.4/2023
5-Year Journal Impact Factor	3.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study.

Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines

Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland

Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.

Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines.

Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE.

Comparative study of immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in Belarus

Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study.

Immune Response in Regard to Hypersensitivity Reactions after COVID-19 Vaccination

Assessment of the factors affecting the clinical outcomes of infection and safety of vaccines against SARS-CoV-2 among Egyptian patients

Similar Documents

Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study.

Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines

Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland

Assessing the long-stand antibody response induced by COVID-19 vaccines: A study in an educational cohort in San Luis, Argentina.

Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines.

Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE.

Comparative study of immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in Belarus

Adverse Effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 Vaccines among the Adult Population in Saudi Arabia: A Cross-Sectional Study.

Immune Response in Regard to Hypersensitivity Reactions after COVID-19 Vaccination

Assessment of the factors affecting the clinical outcomes of infection and safety of vaccines against SARS-CoV-2 among Egyptian patients